<DOC>
	<DOCNO>NCT01180426</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy safety profile tosedostat elderly patient suffer refractory relapse Acute Myeloid Leukemia .</brief_summary>
	<brief_title>Extension Study With Tosedostat Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>Extension protocol OPAL Study ( CHR-2797-038 ) . Study mimic normal clinical practice ; procedures visit therefore mandate protocol . Timing bone marrow assessment also leave investigator 's discretion .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Signed , inform consent Completion Visit 11 OPAL Study ( Month 6 Visit ) Investigator 's opinion subject would benefit continued therapy tosedostat . Any coexist medical condition Investigator 's opinion substantially increase risk associate subject 's participation study Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study Administration ( ) investigational agent within 14 day entry TOPAZ .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Relapse Refractory Acute Myeloid Leukemia</keyword>
</DOC>